Profile data is unavailable for this security.
About the company
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
- Revenue in SEK (TTM)52.67m
- Net income in SEK-383.48m
- Incorporated1997
- Employees112.00
- LocationBioInvent International ABThe Gamma Building, Ideongatan 1LUND 223 70SwedenSWE
- Phone+46 462868550
- Fax+46 462110806
- Websitehttps://www.bioinvent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nykode Therapeutics ASA | 62.42m | -384.98m | 1.58bn | 179.00 | -- | 1.02 | -- | 25.34 | -1.27 | -1.27 | 0.2014 | 4.88 | 0.0333 | -- | 1.59 | 372,422.90 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Nanoform Finland Oyj | 26.02m | -245.75m | 1.58bn | 174.00 | -- | 1.97 | -- | 60.84 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Vicore Pharma Holding AB | 104.24m | -200.07m | 1.59bn | 28.00 | -- | 1.88 | -- | 15.26 | -1.76 | -1.76 | 0.9134 | 3.79 | 0.2546 | -- | 64.15 | 4,343,459.00 | -48.87 | -58.65 | -53.82 | -65.58 | -- | -- | -191.92 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -69.48m | 1.72bn | 5.00 | -- | 6.80 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Nightingale Health Oyj | 41.44m | -204.83m | 1.75bn | 81.00 | -- | 2.57 | -- | 42.19 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
| Devyser Diagnostics AB | 196.00m | -54.20m | 1.94bn | 127.00 | -- | 5.26 | -- | 9.88 | -3.33 | -3.33 | 12.05 | 22.35 | 0.3855 | 1.61 | 5.42 | 1,661,017.00 | -10.68 | -8.97 | -12.15 | -10.15 | 83.11 | 80.14 | -27.70 | -23.91 | 4.01 | -- | 0.1498 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Hansa Biopharma AB | 163.56m | -801.64m | 2.89bn | 146.00 | -- | -- | -- | 17.68 | -14.59 | -14.59 | 2.96 | -3.23 | 0.1368 | 40.48 | 1.43 | 973,589.30 | -67.03 | -47.96 | -88.36 | -56.12 | 42.86 | 64.18 | -490.11 | -835.04 | 3.04 | -9.32 | 1.29 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| BioInvent International AB | 52.67m | -383.48m | 2.90bn | 112.00 | -- | 2.64 | -- | 54.97 | -5.83 | -5.83 | 0.8001 | 16.68 | 0.0377 | -- | 0.8604 | 474,495.50 | -27.41 | -17.50 | -29.50 | -18.64 | -- | -- | -728.09 | -131.63 | 12.18 | -- | 0.0171 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Data as of Sep 20 2024. Currency figures normalised to BioInvent International AB's reporting currency: Swedish Krona SEK
34.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2023 | 10.13m | 15.39% |
| HBM Partners AG (Investment Management)as of 31 Dec 2023 | 5.08m | 7.71% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 4.02m | 6.11% |
| Handelsbanken Fonder ABas of 31 Aug 2024 | 1.69m | 2.56% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 622.60k | 0.95% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2023 | 450.00k | 0.68% |
| SEB Investment Management ABas of 30 Aug 2024 | 344.25k | 0.52% |
| Skandia Investment Management ABas of 31 Jul 2024 | 324.58k | 0.49% |
| FCG Fonder ABas of 30 Aug 2024 | 222.08k | 0.34% |
| Medical Strategy GmbHas of 31 May 2024 | 60.00k | 0.09% |
More ▼
Data from 31 May 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
